Literature DB >> 20578066

Characteristics of HIV-1 non-B subtype infections in Northwest Poland.

Miłosz Parczewski1, Magdalena Leszczyszyn-Pynka, Dorota Bander, Anna Urbańska, Grzegorz Stańczak, Anna Boroń-Kaczmarska.   

Abstract

The number of non-B subtype HIV-1 infections in Europe has been increasing even though major regional differences have been observed. This trend was investigated in northwestern Poland using sequence and epidemiological data from a cohort of 102 HIV-1-infected patients from Szczecin, Poland. HIV-1 subtypes were defined by phylogenetic analysis of viral reverse transcriptase- and protease-partial coding regions, and results were compared with online subtyping by Standford and REGA tools. Subtype analysis using on-line subtyping methods produced varying results if compared to phylogenesis, with concordant variant assignment obtained for 98% (100/102) of sequences by Stanford and 85% (87/102) by REGA. In the population studied, non-B subtype infections comprised 21% of the infections and consisted of subtype D (57%, n = 12), CRF01_AE (19%, n = 4), A and C clades (9.5%, n = 2), and the CRF13_cpx recombinant isolate (4.8%, n = 1). Patients carrying non-B subtypes were predominantly heterosexuals with high percentage (57%) of women observed in the group. All HIV-1 non-B women were Caucasian with majority (83%) of infections acquired in Poland; however, among 12 travelers included in the study a higher proportion of non-B infections was noted (50%, P = 0.01). Moreover, lower baseline lymphocyte CD4 counts (P = 0.01), higher baseline HIV-1 viremia (P = 0.08), and a more advanced stage of the disease (P = 0.03) were observed among individuals infected with non-B subtypes. The data indicated that the proportion of HIV-1 non-B subtype infections was higher than previously reported in Poland consisting of a high subtype D prevalence. Furthermore, subtype D transmission occurred primarily between heterosexual Caucasian individuals from this region. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578066     DOI: 10.1002/jmv.21797

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Molecular surveillance of HIV-1 in Madrid, Spain: a phylogeographic analysis.

Authors:  José M González-Alba; Africa Holguín; Rosa Garcia; Silvia García-Bujalance; Roberto Alonso; Avelina Suárez; Rafael Delgado; Laura Cardeñoso; Rosa González; Isabel García-Bermejo; Francisca Portero; Carmen de Mendoza; Fernando González-Candelas; Juan-Carlos Galán
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

2.  HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis.

Authors:  Miłosz Parczewski; Magdalena Leszczyszyn-Pynka; Dorota Bander; Anna Urbanska; Anna Boroń-Kaczmarska
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

3.  Expanding HIV-1 subtype B transmission networks among men who have sex with men in Poland.

Authors:  Miłosz Parczewski; Magdalena Leszczyszyn-Pynka; Magdalena Witak-Jędra; Bartosz Szetela; Jacek Gąsiorowski; Brygida Knysz; Monika Bociąga-Jasik; Paweł Skwara; Anna Grzeszczuk; Maria Jankowska; Grażyna Barałkiewicz; Iwona Mozer-Lisewska; Władysław Łojewski; Katarzyna Kozieł; Edyta Grąbczewska; Elżbieta Jabłonowska; Anna Urbańska
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

4.  Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.

Authors:  Miłosz Parczewski; Anna Urbańska; Katarzyna Maciejewska; Magdalena Witak-Jȩdra; Magdalena Leszczyszyn-Pynka
Journal:  J Int AIDS Soc       Date:  2014-04-17       Impact factor: 5.396

5.  Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland.

Authors:  Magdalena Leszczyszyn-Pynka; Piotr Ciejak; Katarzyna Maciejewska; Magdalena Witak-Jędra; Malwina Karasińska-Cieślak; Ewa Karpińska; Marta Wawrzynowicz-Syczewska; Miłosz Parczewski
Journal:  Arch Med Sci       Date:  2016-03-23       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.